2024-518685-27-00招募中3 期
EMpagliflozin and daPAgliflozin in patients hospiTalized for acute decompensated Heart failure (EMPATHY) – a phase III Trial
Medical University Of Warsaw14 个研究点 分布在 1 个国家目标入组 1,364 人开始时间: 2024年12月2日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,364
- 试验地点
- 14
- 主要终点
- Composite primary endpoint - time to first event of all-cause death or worsening HF (defined as worsening signs or symptoms of HF that require an intensification of diuretic therapy or any other intravenous therapy for HF or mechanical ventilatory, renal or circulatory support) or HF readmission (unplanned ambulatory visit or hospitalization due to symptoms of HF through 3 months).
研究概览
简要总结
The primary objective is to investigate and compare the impact of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical endpoints in patients hospitalized due to acute/decompensated HF regardless of ejection fraction (HFrEF, HFmEF, HFpEF) or diabetes status.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years of age with the capacity to provide written informed consent
- •eGFR >20 ml/min/1,73m2
- •Currently hospitalized for a primary diagnosis of acute/decompensated HF (HFrEF, HFmrEF,HFpEF), including symptoms and signs of fluid overload regardless of ejection fraction or diabetes status
- •In patients with HFpEF the diagnosis has to be confirmed according to the current HFpEF definition (by non-invasive testing: evidence of structural or functional changes in the heart as evidenced on echocardiography or by invasive testing as LVEDP assessment or right heart catheterisation).
- •Randomized no earlier than 24 hours and up to 10 days after initial presentation while still hospitalized
- •Stable as defined by: systolic blood pressure (SBP>100 mmHg for the preceding 6 hours)
- •No intensification of IV diuretics within the last 6 hours
- •No use of IV vasodilators within the last 6 hours
- •No use of IV inotropes or levosimendan within the last 24 hours prior to randomization
- •Elevated NT-proBNP >600 pg/mL during the current hospitalization in patients with HFrEF and >300 pg/mL in patients with HFmrEF or HFpEF (or above 900 pg/ml if atrial fibrillation is present at admission independently from EF).
排除标准
- •History of ketoacidosis
- •>1 episode of severe hypoglycaemia within the last 6 months under treatment with insulin or sulfonylurea
- •Acute symptomatic urinary tract infection or genital infection
- •Type 1 diabetes
- •SGLT-2 Inhibitor at baseline or known allergy to SGLT-2 Inhibitors
- •Current active cancer with less than 2 years of life expectancy
- •Pulmonary embolism, cerebrovascular accident as the primary trigger for the current hospitalization
- •Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction
- •Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant
- •Blood pH<7.32
结局指标
主要结局
Composite primary endpoint - time to first event of all-cause death or worsening HF (defined as worsening signs or symptoms of HF that require an intensification of diuretic therapy or any other intravenous therapy for HF or mechanical ventilatory, renal or circulatory support) or HF readmission (unplanned ambulatory visit or hospitalization due to symptoms of HF through 3 months).
Composite primary endpoint - time to first event of all-cause death or worsening HF (defined as worsening signs or symptoms of HF that require an intensification of diuretic therapy or any other intravenous therapy for HF or mechanical ventilatory, renal or circulatory support) or HF readmission (unplanned ambulatory visit or hospitalization due to symptoms of HF through 3 months).
次要结局
- Composite endpoint - time to first event of all-cause death or worsening HF (defined as worsening signs or symptoms of HF that require an intensification of diuretic therapy or any other intravenous therapy for HF or mechanical ventilatory, renal or circulatory support) or HF readmission (unplanned ambulatory visit or hospitalization due to symptoms of HF through 9 months
- Difference in the number of recurrent hospitalizations due to heart failure between the treatment groups: at 3 and 9 months
- Difference in the number of hospitalizations for CV causes between the treatment groups: - time frame: at 3 and 9 months.
- Difference in the number of hospitalizations for other than CV causes between the treatment groups: - time frame: at 3 and 9 months.
- Time to adjudicate CV death- time frame: at 3 and 9 months.
- Time to adjudicate all causes of death- time frame: at 3 and 9 months.
- Time to adjudicate myocardial infarction- time frame: at 3 and 9 months
- eGFR (Estimated Glomerular Filtration Rate) (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Equation)) CR slope of change from baseline: at 3 and 9 months
- Difference in the number of hospital readmissions due to heart failure between the treatment groups- time frame: at 3 and 9 months
- Difference in the number of hospital readmissions for any cause between the treatment groups- time frame: at 3 and 9 months
- Difference in the duration of hospital stay between the treatment groups after initiation of the study treatment- time frame: at 3 and 9 months.
- Difference in the number of incidences of new onset AF and re-occurrence of AF between treatment groups- time frame: at 3 and 9 months.
- Difference in the change of ejection fraction in echocardiography between treatment groups from randomization to 3 and 9 months
- Difference in the change of left ventricular diastolic function in echocardiography from randomization to 3 and 9 months.
- Difference in the change of LV strain analysis in echocardiography from randomization to 3 and 9 months.
- The time-averaged proportional change in NT-proBNP from baseline through 3 and 9 months.
- Personalized medicine based on biomarker approach- the time-averaged proportional change in selected ncRNA expression linked to hypertrophy, inflammation, fibrosis, apoptosis, electric stability between treatment groups and placebo group from baseline through months 3 and 9.
- Personalized medicine based on biomarker approach- the time-averaged proportional change in PCT- procalcitonin, ANP - atrial natriuretic peptide, FGF-23 - fibroblast growth factor-23, GDF-15 - growth differentiation factor-15, IL-2 - interleukin 2, IL-6 - interleukin 6 between treatment groups and placebo group from baseline through months 3 and 9.
- Personalized medicine based on biomarker approach- association between primary and secondary clinical endpoints and microbiome metabolites at baseline in both treatment groups and placebo in long term follow-up (3 and 9 months).
- Personalized medicine based on biomarker approach- association between primary and secondary clinical endpoints and metabolome at baseline in both treatment groups and placebo in long term follow-up (3 and 9 months).
- Cost-effectiveness substudy.
- Effect of SGLT-2 inhibitors according to clinical characteristics as age, gender.
- Symptoms, Function, and Quality of Life substudy
- Polypharmacy substudy
- Effect of SGLT-2 inhibitors on cardiac muscle fibrosis based on magnetic resonance (MR) substudy.
研究者
Marek
Scientific
Medical University Of Warsaw
研究点 (14)
Loading locations...
相似试验
招募中
2 期
the EMPOWER StudyHyponatremia2023-508610-42-00Universitaetsspital Basel60
招募中
3 期
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureAcute Decompensated Heart FailureNCT05776043Medical University of Warsaw1,364
招募中
4 期
GliflOzin in eLderly Diabetic patiENts: A praGmatic intraclass Evaluation trial2024-518915-20-00Center For Outcomes Research And Clinical Epidemiology S.r.l.1,167
已完成
4 期
The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction2022-501682-45-00University Hospital Maastricht48
招募中
3 期
Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute decompensated heart failureacute decompensated heart failure2024-517977-26-00Friedrich-Schiller-Universitaet Jena556